Home
News & Events
Press releases

Press releases

Connect with us

Contact us
Submit proposal request
Update Email Preferences
Global office locator
ICON on social media

What’s happening in ICON

In this new blog series, we review ISO 14971 (Application of risk management to medical devices) - its history, the principles embedded within it and how it relates to other standards and regulation. For the first editio...

4 Nov

View post

View webpage

ICON Plc

Meet ICON experts at the AASLD to learn how ICON partners with sponsors, investigators, patients and other collaborators to deliver strategic, data-driven solutions for MASH and hepatology studies. https://ow.ly/9QBn50X8...

4 Nov

View post

View webpage

ICON Plc

Digital measures, including digital biomarkers and digital endpoints, offer sponsors powerful ways to assess treatment effect in real time, in the real world. But to be meaningful, those measures must be carefully selec...

4 Nov

View post

View webpage

ICON Plc

Teams incorporating DHTs into their protocol design may grapple with the question of how to transform raw sensor data into a validated, regulatory-ready digital endpoint. Start with the V3 framework: 🔬 Verification 📊...

4 Nov

View post

View webpage

ICON Plc

The PHUSE single day event in Bloemfontein will bring together leading professionals to explore innovations shaping clinical data science. ICON is proud to contribute to these discussions, focusing on topics such as digi...

4 Nov

View post

View webpage

ICON Plc

Post-marketing pharmacovigilance plays a crucial role in maintaining patient safety once a product reaches the market. While automation can streamline certain tasks, its implementation must be carefully managed to avoid ...

4 Nov

View post

View webpage

ICON Plc

Early clinical trial designs—especially first-in-human (FIH) studies—are increasingly tailored to the unique needs of specific therapeutic areas. In neurodegenerative diseases, there is a growing shift toward flexible an...

4 Nov

View post

View webpage

ICON Plc

ICON is proud to be recognised among the top global companies in the world for female employees. As of 31 December 2024, women make up 70% of our workforce and hold 60% of director-level and above roles—a powerful refle...

4 Nov

View post

View webpage

ICON Plc

By prioritising community engagement, enabling remote enrollment, and clearly communicating risks and benefits, researchers and sponsors can help create safer, more inclusive clinical trials for pregnant individuals. Exp...

3 Nov

View post

View webpage

ICON Plc

Planning an Integrated Summary of Safety and Efficacy (ISS/ISE) submission can be demanding, especially when studies differ in format or terminology. This blog explains how early preparation and the right integration str...

3 Nov

View post

View webpage

ICON Plc

Connect with ICON experts at #ObesityWeek, booth \#520 to learn about our proven success designing and executing early phase studies, supported by a robust database of overweight/obese volunteers and in-house clinical re...

3 Nov

View post

View webpage

ICON Plc

Over the past five years, ICON has participated in over 840 oncology and haematologic malignancy, and 83 non-malignant haematology, clinical studies globally. Meet ICON experts at #ASH25, booth \#2161 to learn how our fl...

3 Nov

View post

View webpage

Press releases

ICON completes acquisition of MediMedia Pharma Solutions

ICON to acquire MediMedia Pharma Solutions

In this section

Connect with us

What’s happening in ICON